Manuscript Writing Service
International Journal of Surgery Science
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Surgery Science
Vol. 3, Issue 1, Part B (2019)

Risk of urolithiasis due to topiramate as weight loss drug

Author(s): Jaideep M Ratkal and Elias Sharma
Abstract: Topiramate is sulfamate-substituted monosaccharide anti-epileptic and migraine drug, recently FDA approved as an anti-obesity medicine. Many reports of symptomatic urolithiasis with Topiramate usage as anti-epileptic and migraine drug are available including those studies with biochemical and stone risk profile. We present cases of symptomatic urolithiasis in patients on Topiramate for weight loss and to express caution that the drug usage should be limited and accompanied by assessment of risk profiles at regular intervals.
Pages: 77-78  |  1108 Views  246 Downloads
How to cite this article:
Jaideep M Ratkal, Elias Sharma. Risk of urolithiasis due to topiramate as weight loss drug. Int J Surg Sci 2019;3(1):77-78. DOI: https://doi.org/10.33545/surgery.2019.v3.i1b.15
International Journal of Surgery Science